'Chaotic' REACH processes need to be addressed – AmCham EU
US trade body urges Commission to make improvements
The chemicals industry and society are being damaged by the "very high level of uncertainty" brought about by REACH processes, the American Chamber of Commerce in Brussels (AmCham EU) says.
In its submission to the European Commission’s second REACH review, the organisation says despite efforts made by the EU executive, Echa and member states, the implementation of REACH processes "remains somewhat chaotic". And, it adds, this can lead to inconsistencies or contradictions.
AmCham EU is one of several industry groups, NGOs and public sector bodies, to submit comments to the consultation. The review's findings are due to be completed later this year.
It is "particularly difficult", it goes on, to see why the same substance would be targeted by different processes led by different member states. "We would encourage the Commission and Echa to clarify everyone’s obligations and rights."
It adds that "significant improvements" are needed in predictability to support investment in existing and new substances.
And in its general comments on the REACH review, the American Chemistry Council (ACC) also calls for simplified and improved implementation. It notes that "a perceived lack" of robust evaluation of hazard data – rather than risk – leads to substances essential for health, such as Vitamin D, being identified as hazards.
Both US bodies want improvements to guidance documents. The ACC says "more transparency" is needed and stakeholders should be given multiple opportunities to provide input into documents. AmCham EU says it is not clear whether industry comments are even considered in the final decisions.
The Commission and Echa should take on a more “"central role"in implementing REACH by consulting with registrants and other stakeholders for major substances, AmCham EU says.
It adds that it "deplores" significant regulations being advanced outside of REACH that "jeopardise the legitimacy of the entire REACH framework", citing developments to the occupational safety and health (Osh) directive and Classification, Labelling and Packaging (CLP) Regulation.
Overlaps between REACH and other EU legislation, ACC says, often lead to "inconsistencies and deadlocks", such as those between REACH and Osh. One example, AmCham EU says, is where Echa's risk assessment committee (Rac) and DG Employment's Scientific Committee on Occupational Exposure Limits (Scoel) "continuously apply different limit values" as their methodologies differ on the reprotoxic solvent 1-methyl-2-pyrrolidone (NMP).
Eye on enforcement
Compliance checks sometimes lead to "multi-year processes with no predictability of compliance", AmCham EU says. REACH restrictions, if not enforced, are a "de facto competitive advantage" for non-compliant European and third-country industries, it adds.
For example, the restriction on polycyclic aromatic hydrocarbons (PAHs) has meant that tyre companies manufacturing in Europe, including US ones, have spent more than €100m on research, development and testing for compliance and alternatives assessment, it says.
Competent authorities must be constantly updated on the most recent interpretation of the Regulation and apply guidelines agreed at EU level, AmCham EU says. And better training of enforcement officials and greater coordination between different departments of national competent authorities is needed.
2026-10-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
关于加强防范钓鱼邮件的通知 Notification on Strengthening Anti-Phishing Measures
-
US Tariff Pressure on Canada Raises Risks for North American Chemical Supply Chains
-
Four Fine Chemical Units of Huajin Aramco Project – HDPE, EO/EG, etc. – Reach Mechanical Completion
-
关于将二氟乙咪酯等16种物质列入《非药用类麻醉药品和精神药品目录》的公告 Announcement on the Inclusion of 16 Substances including Difluoroetomidate in the Catalogue of Non-Medicinal Narcotic Drugs and Psychotropic Substances
-
U.S. Section 232 Pharmaceutical Tariffs Take Effect, With 100% Base Rate on Patented Drugs and APIs
-
U.S. and China Reach Consensus on More Favorable Tariff Treatment for $30 Billion of Goods Each Way
-
South Korea and Japan Launch Energy Supply Chain Cooperation as Hormuz Risks Grow
-
China’s 15th Five-Year Plan Sets New Priorities for Pharmaceutical Innovation and Supply Chains
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
Trump Urges Ukraine to Halt Russian Refinery Strikes as Diesel Shortage Becomes a Global Policy Issue
Recommend Reading
-
Pakistan Launches Successive Anti-dumping Investigations against Chinese Products, Involving Soda Ash, Ibuprofen and Other Raw Materials
-
Japan Tightens the Rules—Then Loosens Them: A Surprising Shift in Food Additive Policy
-
The End of Hype: Europe’s Bio-stimulant Industry Faces a Science-First Reckoning by 2030
-
FDA Orders Removal of “Suicidality Warning”: Are Weight-Loss Blockbusters Finally Cleared—or Is Regulators Giving the Market a Reality Check?
-
U.S. Formally Publishes India PFA Trade Cases, Raising New Barriers for Fluoropolymer Supply
-
Business Society September 23, 2026 Polyester Staple Fiber Trend Analysis: Clear Downtrend
-
Business Society September 23, 2026 Dichloromethane Trend Analysis: Rebound (Bearish)
-
Premium Global Chemical Sourcing Requests (28-31May, 2026)
-
Business Society September 23, 2026 Caustic Soda Trend Analysis: Slightly Bullish with Volatility
-
Downside Pressure on Costs Leads to Weekly Drop in Polyester Bottle Flakes Prices (Nov. 17-21)